相关实验视频
Updated: Jun 29, 2025

05:16
Sleeve Gastrectomy in Mice using Surgical Clips
Published on: November 14, 2020
6.6K
探索腹部外科手术对减肥和糖尿病的影响:和葡萄糖受体调节
Austin Cottam1,2, Daniel Cottam1,2, Mitchell Roslin1,2
1Bariatric Medicine Institute, Salt Lake City, Utah, USA. (Drs A. Cottam, D. Cottam, and Surve).
概括
腹腔外科手术改变了肠道葡萄糖运输体 (SGLT和GLUT),影响了体重减轻. 了解这些变化可以个性化手术方法,以更好地管理糖尿病和减肥结果.
科学领域:
- 内分泌学 在内分泌学.
- 胃肠病学 胃肠病学
- 代谢手术 代谢手术
背景情况:
- -葡萄糖共运输体 (SGLT) 和葡萄糖运输体 (GLUT) 调节肠道葡萄糖的吸收.
- 腹腔外科手术显著改变胃肠道解剖学,可能会影响SGLT和GLUT活动.
- 这些输送器修改代表了一个关键的生理机制,有助于手术后减肥.
研究的目的:
- 审查目前关于SGLT和GLUT受体在减肥手术后减肥作用的文献.
- 探索遗传,药理和手术因素如何影响SGLT/GLUT受体活性.
- 根据患者个体需求,为优化减肥手术提供洞察力.
主要方法:
- 对遗传学研究,药理学抑制数据和手术结果分析的文献综述.
- 检查改变胃肠道解剖学对SGLT和GLUT受体功能的影响.
- 对与SGLT/GLUT活动相关的生理调节的分析.
主要成果:
- 腹腔外科手术诱导的解剖变化调节SGLT和GLUT受体活性.
- 改变的葡萄糖输送器功能对减肥有显著的贡献.
- 由于对SGLT/GLUT的影响不同,不同的减肥手术可能会产生不同的影响.
结论:
- 了解SGLT-1,GLUT-2和GLUT-5受体的作用对于减肥手术至关重要.
- 针对这些葡萄糖运输体可能会导致改进的外科手术技术.
- 根据SGLT/GLUT配置文件个性化减肥手术可能会改善患者的治疗结果.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
196
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
196
Carbohydrate Metabolism
11.1K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
11.1K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
174
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
174
Diabetes: Management and Pharmacotherapy
277
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
277
Glucagon-like Receptor Agonists
321
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
321
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K

